Diadenosine Polyphosphates and Mucin Associated With Ocular Surface Disorders
NCT ID: NCT03731624
Last Updated: 2018-11-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
50 participants
OBSERVATIONAL
2018-01-01
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
While the importance of mechanical stress in ocular surface disorder has been reported, the specific molecule involving the pathogenesis is still unknown. Diadenosine polyphosphates are a family of dinucleotides. They can enhance tear secretion and increase corneal wound healing rate from previous reports. Shear-stress stimuli was also noted to be able to induce diadenosine polyphosphates releasing from human corneal epithelium. In addition, mucin, one of the three components of tear film, has been greatly emphasized in the pathogenesis of dry eye disease. There are also some reports about the shearing force compensating the mucin contents in the inflammatory lung/bowel diseases. If diadenosine polyphosphates or mucin indeed play a role in mechanical stress-related ocular surface disorders, it will be a promising therapeutic targeting in the future.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Role of Cytokines and Mast Cell in the Pathogenesis of SLK, Conjunctivochalasis, and Dry Eye
NCT02160327
Ocular Surface Disease in Chronic Graft-Versus-Host Disease (GVHD) Patients
NCT02712762
Investigation on Medical Management of Dry Eye Patients
NCT01942226
The Pathogenesis of Superior Limbic Keratoconjunctivitis
NCT00167050
Dermatologic Tacrolimus Ointment on Eyelids in the Treatment of Refractory Vernal Keratoconjunctivitis and Atopic Keratoconjunctivitis
NCT03557203
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Great impact of ocular surface disorders on quality of life 1.1. Impact of dry eye disease Dry eye disease (DED) is a common ocular surface disorder. Vision-related quality of life in dry eye patients is impaired and is correlated with anxiety and depression.1 Patients with DED are often evaluated by a symptom scale called ocular surface disorder index (OSDI). The OSDI is a valid and reliable scale for diagnosis and measurement of the severity of DED or other ocular surface disorder. It is also a convenient option for clinical use as a result of its shorter completion time.
1.2. Impact of GVHD GVHD caused by alloreactive donor T cells is an important cause of nonrelapse mortality and morbidity after allogeneic hematopoietic cell transplantation (HCT). Ocular GVHD reportedly occurs in more than 50% of allogeneic HCT recipients with chronic GVHD. It can affect all parts of the eye, but the ocular surface is the most common level of involvement. Yoshi et al suggested strong correlations of serial changes in the NIH eye score, the OSDI, and the Lee eye subscale. Given that the OSDI consists of 12 items instead of the 3 for the Lee eye subscale, they found little basis for recommending the OSDI to measure change in the activity of ocular GVHD. Therefore, the Lee eye subscale might be a good choice for determining the impact of ocular GVHD on quality of life.
1.3. Impact of SLK SLK is an ocular surface disorder characterized by unilateral or bilateral redundancy of the superior bulbar conjunctiva with inflammation of the superior tarsal and bulbar conjunctiva. There are many patients suffering by the symptoms of SLK because of its unclear etiology and no standard treatment. In addition, SLK is not easy to make a definite diagnosis, the impact of SLK on quality of life could be underestimated.
2. Mechanical stress from eyelid blinking may be an aggravating or contributing factor of ocular GVHD and SLK 2.1. The symptoms of ocular GVHD relieved by bandage soft contact lens (BSCL) application via the isolation from mechanical stress (eyelid blinking) and ocular surface The standard treatment of ocular GVHD is still not in consensus. Because of the immune reaction participating in the pathogenesis of ocular GVHD, some topical immunosuppressants, such as cyclosporine A (CsA) and tacrolimus, are applied on the patients with ocular GVHD. Allogeneic serum eye drops and autologous plasma rich in platelet-derived growth factor (PDGF) eye drops were also reported to be effective in chronic ocular GVHD patients. For medication refractory cases, punctal plugs, scleral lens, and bandage soft contact lens (BSCL) could be applied as alternative treatments for ocular GVHD patient. According to previous report, BSCL is a safe and effective treatment option that improves manifestations of ocular GVHD. BSCL can act as a barrier to further epithelial disruption and corneal nerve stimulation by the shearing force of the upper lid during the blink.
2.2. Mechanical stress plays a role in the pathogenesis of SLK Mechanical stimulation may contribute to the pathogenesis of SLK. We speculated that this kind of physical trauma not only results in the keratinization of conjunctival epithelium, but also induced inflammatory cells and mediators, such as mast cells and cytokines, respectively. Three out of 8 SLK patients benefitted from large diameter contact lens application. Conjunctival resection with Tenon's capsule excision was also reported as a beneficial treatment for medication refractory SLK patients.
3. The expression of diadenosine polyphosphates and mucin may alter the clinical presentation or diagnosis of ocular surface disorders 3.1. Dinucleoside polyphosphates in ocular surface disorder Diadenosine polyphosphates are a family of dinucleotides, consisting of two adenosine nucleosides joined by a phosphate chain whose length can vary from 2 to 7 phosphates. They are released from nerve terminals to the extracellular milieu where they can exert actions by interacting with purinergic receptors.
Since the levels of diadenosine tetraphosphate (Ap4A) and diadenosine pentaphosphate (Ap5A) in tears were found to be greater in all dry eye patients, these compounds could be objective markers to score dry eye. In the forced blink experiments, concentrations of the diadenosine polyphosphates rose with increasing blink frequency.13 In addition, topical application of diadenosine tetraphosphate was also noted to be able to stimulate tear secretion in vivo. Because of the higher levels of Ap4A found in refractive surgery patients during the first day after the surgery, this dinucleotide release might help in the wound healing process as well.
3.2. Mucin in ocular surface disorder Mucin plays an important role over the ocular surface. It converts the hydrophobic corneal surface to a hydrophilic surface by adhering to the glycocalyx on the corneal microvilli. It also contributes differently to the protection of the ocular surface against allergens, pathogens, extracellular molecules, abrasive stress, and drying. MUC1 (mucin 1), 2, 4, 5AC, and 7 are the subtypes of mucin that can be found over ocular surface, including cornea, conjunctiva, goblet cell, and lacrimal gland.
Ocular surface pathologies, i.e. dry eye syndrome or allergic conjunctivitis, are reportedly associated with alteration of expression pattern of mucin components. Although dryness of the ocular surface is a fundamental situation, local inflammation in the epithelium plays critical roles in the pathogenesis and symptom in patients with dry eye syndrome. Mucin deficiency can lead to inflammation in the ocular surface. Expression of MUC1, MUC2, MUC4, and MUC5AC are significantly lower in conjunctival epithelium gathered by impression cytology in the patients with dry eye syndrome compared with that in normal subject.18 Reduction of MUC1 expression in dry eye local tissue is reportedly most prominent and could be a marker for diagnosis or evaluation of the disease severity. Topical eye drop of Rebamipide, a drug that is capable of stimulating of mucin secretion in gastrointestinal tract or conjunctiva, is approved in Japanese government for use in the treatment of dry eye diseases.
Mucin was also reported as an important factor contributing to some allergic keratoconjunctivitis. In the patients with atopic keratoconjunctivitis, expression of goblet cell-specific mucin, MUC5AC mRNA, was reduced and MUC16 mRNA expression was upregulated in brush cytology specimens. Besides, patients with vernal keratoconjunctivitis had increased numbers of conjunctival goblet cells from impression cytology specimen. This phenomenon also altered the levels of mucin over the ocular surface.
4. Mechanical stress can violate the levels of diadenosine polyphosphates and mucin 4.1. Diadenosine polyphosphate under mechanical stress It is known that cells under stress accumulate various dinucleoside polyphosphates, compounds suggested to function as alarmones. The release of diadenosine polyphosphates to the tears can be caused by shear stress, such as that corneal epithelial cells release these molecules as a consequence of the lid contact during the blinking process. Daily wear of rigid gas permeable lenses also can increase the levels of Ap4A due to mechanical stimulation by blinking of the corneal epithelium, and this is associated with discomfort.
4.2. Mucin under mechanical stress Gastrointestinal tract and upper airway are the organ systems filled with mucin as an important protection. MUC1 and MUC4 in the colon and MUC3 in the duodenum were upregulated in stressed animals. These findings suggest that chronic stress may affect mucin expression in the gastrointestinal tract. In addition, human bronchial epithelial cell cultures (HBECCs) are very sensitive to the mechanical stress associated with handling and pipetting. Mucin secretion at baseline in vivo occurs in a mechanically dynamic lung environment: goblet cells are exposed continuously to mechanical forces, shear stress and compressive stress, that may stimulate and/or influence the production and secretion of mucins.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SLK
No interventions assigned to this group
GVHD
No interventions assigned to this group
Dry eye
No interventions assigned to this group
Control
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diagnosis of dry eye disease, ocular GVHD, and SLK
* patients who ever received topical medications, including artificial tears and topical steroids, at least 3 months, but refractory to the treatment
* absence of new systemic immunosuppressive medications within 1 month
Exclusion Criteria
* absolute neutrophil count less than 1000/mL
* known hypersensitivity or allergy to contact lens care products
* treatment with scleral lenses within the previous 3 months
* evidence of any active infection in the eyes
* receiving any ocular surgeries within the previous 3 months
18 Years
99 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
yichensun
Principal Investigator, Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yi-Chen Sun, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Taipei Tzu Chi Hospital
New Taipei City, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TCRD-TPE-107-07
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.